Trial record 14 of 32 for:    "von Willebrand disease"

Optivate in People With Von Willebrand Disease Undergoing Surgery

This study has been terminated.
(Due to slow recruitment and a delay in reaching the recruitment target.)
Sponsor:
Information provided by:
Bio Products Laboratory
ClinicalTrials.gov Identifier:
NCT00404300
First received: November 27, 2006
Last updated: March 2, 2010
Last verified: March 2010
  Purpose

An open, multi-centre study in patients with von Willebrand Disease (VWD) undergoing surgery.


Condition Intervention Phase
Von Willebrand Disease
Drug: Optivate
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Multi-centre Study to Investigate the Safety and Efficacy of OPTIVATE®, a High Purity, Dual Inactivated Factor VIII and Von Willebrand Factor Concentrate, in Patients With Von Willebrand Disease Who Are Undergoing Surgery

Resource links provided by NLM:


Further study details as provided by Bio Products Laboratory:

Primary Outcome Measures:
  • A subjective overall assessment by the investigator of OPTIVATE® in the control of bleeding due to surgery throughout the whole study. [ Time Frame: Throughout the whole study ]

Estimated Enrollment: 25
Study Start Date: February 2007
Study Completion Date: September 2008
Intervention Details:
    Drug: Optivate
    Plasma-derived Factor VIII
  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Have given written informed consent.
  2. Be aged 12 years or older.
  3. Have VWD of known type.
  4. Be due to undergo surgery, in which the investigator believes a VWF concentrate will be required.
  5. Have a known lack of, poor response to, or contraindication to, DDAVP, or require a type of surgery in which a plasma-derived product is appropriate.
  6. Have a prothrombin time (PT) of not more than 3 seconds above the upper limit of the reference range.
  7. Female patients of child-bearing potential, with the exception of pregnant patients undergoing Caesarean surgery or other modes of delivery, including normal vaginal delivery, must have a negative result on a human chorionic gonadotropin-based pregnancy test. If a female patient is or becomes sexually active, she must practice contraception by using a method of proven reliability for the duration of the study.

Exclusion Criteria:

  1. Have a history of inhibitor development to VWF or FVIII or a positive result at screening (positive screen for VWF inhibitor; positive screen and a result of >0.5 BU for FVIII inhibitor). A result at screening is not mandatory if the patient is to undergo emergency surgery and the local laboratory is unable to perform the analyses.
  2. Patients with thrombocytopenia (platelets <50 x 109/L).
  3. Patients who have clinically significant renal disease (creatinine >200 µmol/L).
  4. Patients who have clinically significant liver disease (ALT levels greater than three times the upper limit of the reference range).
  5. Presence of any other major systemic illnesses which would compromise the outcome of the study in the opinion of the investigator.
  6. Known or suspected hypersensitivity to investigational medicinal product (IMP) or its excipients.
  7. Have a recent history of alcohol or drug abuse.
  8. Administration of a new chemical entity within the 4 months preceding enrolment.
  9. Participation in any other clinical study in which investigational or marketed drugs were employed in the 30 days preceding enrolment (screening visit) into this study, with the exception of the BPL clinical study Protocol 8VWF01.
  10. Female patients who are lactating.
  11. In the opinion of the investigator, the patient is unlikely to comply with the study protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00404300

Locations
Israel
Rambam Health Care Campus, 8 Haaliya St., Bat-Galim
Haifa, Israel, 31096
Haddasah Ein-Karem Medical Center, P.O.Box 12000
Jerusalem, Israel, 91120
Beilinson Hospital, Rabin Medical Center, 39 Jabotinsky Street
Petah Tikva, Israel, 49100
United Kingdom
Katharine Dormandy Haemophilia Centre and Haemostasis Unit, Royal Free Hospital
London, United Kingdom, NW2 3QG
Sponsors and Collaborators
Bio Products Laboratory
Investigators
Principal Investigator: Thynn Thynn Yee Royal Free Hospital NHS Foundation Trust
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00404300     History of Changes
Other Study ID Numbers: 8VWF03
Study First Received: November 27, 2006
Last Updated: March 2, 2010
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Von Willebrand Diseases
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Blood Platelet Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Factor VIII
Coagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 28, 2014